Global Fentanyl Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030.
The market growth of cancer-related products and services is strongly influenced by the increasing prevalence of cancer globally. In 2022, the United States is estimated to witness approximately 1.9 million newly diagnosed cancer cases, emphasizing the significant impact of this disease on individuals and communities within the country. Additionally, it is projected that there will be 609,360 cancer-related deaths in the same year. The rising awareness of cancer, coupled with advancements in medical research and the development of new treatments, further contributes to the growth of the market. Governments worldwide are recognizing the urgent need to address cancer as a leading cause of premature death, leading to increased investment in initiatives and programs aimed at reducing cancer mortality rates.
The combination of these factors, including the increasing prevalence of cancer, heightened awareness, advancements in treatments, and greater investment in medical research, collectively drive the market growth of cancer-related products and services. As the global fight against cancer intensifies, the market is poised to expand to meet the growing demand for effective prevention, diagnosis, treatment, and supportive care.
Furthermore, the projected rise in global healthcare expenditure is anticipated to drive the expansion of the global fentanyl market. Industry experts have indicated that the average total health spending per person worldwide was approximately USD 1,129 USD in 2019. This figure is estimated to grow to USD 1,515 by 2050. The increase in healthcare spending signifies a greater allocation of resources towards medical treatments and pharmaceuticals, which is likely to contribute to the growth of the fentanyl market. Moreover, the implementation of awareness campaigns focusing on the therapeutic benefits of fentanyl is expected to further enhance the market’s potential for expansion during the forecast period. These campaigns aim to educate healthcare professionals and the public about the appropriate and responsible use of fentanyl in managing pain and improving patient outcomes. By increasing awareness about the safe and effective utilization of fentanyl, these initiatives can potentially stimulate demand for the product and drive market growth.
The key regions considered for the Global Fentanyl Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. By the end of 2030, the North American fentanyl market is projected to capture the largest market share. This dominance in the region can be attributed to several factors, including population growth, research activities, and the availability of health insurance coverage for various cancer diagnoses. The region’s growing population provides a larger patient pool for medical treatments, including fentanyl usage. Additionally, the presence of extensive research activities in North America supports the development and adoption of advanced pharmaceuticals, including fentanyl, further driving market growth.
The rising economic status and affordability of advanced cancer treatments in North America also contribute to market expansion. The United States, for instance, witnessed an increase in personal income and spending, indicating the financial capacity to access advanced treatments. In 2019, the country reported a significant number of new cancer cases and cancer-related deaths, underlining the demand for effective pain management options such as fentanyl. Furthermore, insurance companies in North America offer efficient reimbursement policies for cancer treatments, incentivizing patients to opt for advanced treatment methods. This favorable reimbursement environment plays a significant role in encouraging patients to choose fentanyl and other advanced therapies, thus contributing to the market’s growth in the region.
Major market player included in this report are:
Thermo Fisher Scientific Inc.
Boehringer Ingelheim GmbH
Bayer AG
Novartis AG
Sanofi-aventis Groupe
Abbott Laboratories
Merck & Co., Inc.
Validus Pharmaceuticals LLC
Teva Pharmaceutical Industries Ltd.
Siemens Healthcare GmbH
Global Fentanyl Market Report Scope:
ü Historical Data – 2020 – 2021
ü Base Year for Estimation – 2022
ü Forecast period – 2023-2030
ü Report Coverage – Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
ü Segments Covered – Route of administration, Enduse and Region
ü Regional Scope – North America; Europe; Asia Pacific; Latin America; Middle East & Africa
ü Customization Scope – Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Route of Administration:
Sublingual Tablet
Buccal Tablet
Oral Film
Others
By Enduse:
Hospital
Oncology Centers
Surgical Centers
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa